{"id":106,"date":"2014-04-23T18:54:17","date_gmt":"2014-04-23T18:54:17","guid":{"rendered":"http:\/\/hfhpulm.com\/info\/?p=106"},"modified":"2014-05-01T19:27:02","modified_gmt":"2014-05-01T19:27:02","slug":"ild-research-trials","status":"publish","type":"post","link":"https:\/\/hfhpulm.com\/info\/?p=106","title":{"rendered":"ILD Research Trials"},"content":{"rendered":"<p><a title=\"More info at Clinicaltrials.gov\" href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01769196?term=IPF%2C+gilead%5C&amp;rank=2\" target=\"_blank\">Simtuzumab<\/a>\u00a0trial (RAINIER, Gilead sponsored) is actively recruiting.<\/p>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">In brief, the study is a multicenter, <\/span><span style=\"color: black;\"><b>phase 2 randomized, double-blind, placebo-controlled trial of a subcutaneous LOXL2 monoclonal antibody in patients with Idiopathic Pulmonary Fibrosis (IPF) up to 180 weeks.<\/b><\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\"><b>\u00a0<\/b><\/span><\/span><\/div>\n<div><span style=\"color: black; font-family: Calibri, sans-serif; font-size: small; line-height: 1.5em;\">Roel will be screening clinics to look for potentially suitable candidates but would contact you to check if contacting the patient would be acceptable.<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">\u00a0<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">If you have a patient who might be interested in the study, please contact Roel Almario<\/span><span style=\"color: black;\">\u00a0 with the patient&#8217;s name and MRN , so he may discuss the study with the patient.<\/span><\/span><\/div>\n<div><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">We will be reviewing any possible cases\u00a0in Multidisciplinary ILD conference (there is also a central review process once patients have signed informed consent.)<\/span><\/span><\/div>\n<div><\/div>\n<div>\n<div id=\"divIP1\">\n<div id=\"divExp\">\n<div id=\"divBdy\">\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">Please let me know if you have any questions.<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">\u00a0<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">Thank you,<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">Krishna Thavarajah <\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\"><br \/>\n<\/span><\/span><\/span><\/span><\/span><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\"><br \/>\n<\/span><\/span><\/span><\/span><\/div>\n<div><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">\u00a0<\/span><span style=\"font-family: Calibri, sans-serif; font-size: small;\">\u00a0<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Krishna Thavarajah, MD MS<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Medical Director, Pulmonary Clinics<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Director, Interstitial Lung Disease Program<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Division of Pulmonary and Critical Care Medicine<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Henry Ford Hospital<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">\u00a0<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Clinical Assistant Professor <\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Wayne State University School of Medicine<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simtuzumab\u00a0trial (RAINIER, Gilead sponsored) is actively recruiting. In brief, the study is a multicenter, phase 2 randomized, double-blind, placebo-controlled trial of a subcutaneous LOXL2 monoclonal antibody in patients with Idiopathic Pulmonary Fibrosis (IPF) up to 180 weeks. \u00a0 Roel will be screening clinics to look for potentially suitable candidates but would contact you to check [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,8,19],"tags":[],"class_list":["post-106","post","type-post","status-publish","format-standard","hentry","category-clinic","category-ild","category-research"],"_links":{"self":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=106"}],"version-history":[{"count":9,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/106\/revisions"}],"predecessor-version":[{"id":115,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/106\/revisions\/115"}],"wp:attachment":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}